U.S. Opioids Market, By Drug Type (Oxycodone, Hydrocodone, Morphine, Codeine, Methadone, and Others), By Therapeutic Application (Pain Management, Cough Treatment, and Diarrhea Treatment), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Published In : May 2024

Code : CMI1048

Pages :156

Formats :

Excel and PDF

Industry : Pharmaceutical

Key Developments

In August, 2023, Emergent BioSolutions Inc., a multinational specialty biopharmaceutical company, announced that the NARCAN Naloxone hydrochloride (HCl) Nasal Spray 4 mg is available on shelves nationwide in U.S. and online in September, 2023. NARCAN Nasal Spray, with the same safe and effective 4 mg formulation, device design, and original prescription dose, can reverse the effects of opioids including fentanyl. NARCAN Nasal Spray has a manufacturer’s suggested retail price (MSRP) of US$ 44.99 each carton, roughly US$ 22.50 per dose.
In January, 2023, Hikma Pharmaceuticals PLC, an international pharmaceutical company, announced the launch of Naloxone Hydrochloride Injection, USP, 2mg/2mL in prefilled syringe (PFS) form. The drug that was launched in the U.S. and can be used for the emergency treatment of a known or suspected opioid overdose. Hikma Pharmaceuticals PLC's portfolio of addiction therapy treatments includes a naloxone vial and KLOXXADO (naloxone HCl) nasal spray 8mg, as well as buprenorphine and methadone medication options to meet the urgent needs of U.S. patients and communities.
In March 2021, U.S. Food and Drug Administration (FDA) approved hydrocodone bitartrate tablet, indicated for the management of pain manufactured by Alvogen, a U.S.-based company that focuses on developing, in-licensing, manufacturing, and marketing pharmaceutical products
In November 2020, the U.S. Food and Drug Administration (FDA) approved Arymo ER (morphine sulfate) tablets C-II for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.